WesBanco Investment Department
+1.60%
3M Return
$114.840
+2.354 (+2.05%)At close
The Marzetti Company, formerly Lancaster Colony Corporation, is a manufacturer and seller of specialty food products. The Company’s retail brands Marzetti, New York Bakery, and Sister Schubert’s, Olive Garden, dressings, Chick-fil-A sauces and dressings, Buffalo Wild Wings sauces, Arby’s sauces, Subway sauces, Texas Roadhouse steak sauces, and frozen rolls. Its foodservice business supplies many restaurant chains in the United States with dressings, sauces, breads and frozen pastas.
Marzetti Co is not a strong buy right now due to mixed earnings results and declining sales, despite a recent net income growth to $48.29 million, or $1.76 per share. The current price of $114.84 is significantly below the analyst price target of $130, indicating potential upside, but the company faces risks with a 2.2% decline in sales and a forward P/E of 36.10, suggesting overvaluation. The main risk is the declining sales trend, which could impact future earnings.

Marzetti Co Reports Q4 2026 Earnings with Mixed Results

Marzetti Reports Q4 Net Income Growth Despite Sales Decline

Marzetti Company Reports Fiscal Year 2026 Results

Marzetti Company Declares Quarterly Cash Dividend

Marzetti Company to Release Q4 and FY 2026 Financial Results
The Marzetti Company, formerly Lancaster Colony Corporation, is a manufacturer and seller of specialty food products. The Company’s retail brands Marzetti, New York Bakery, and Sister Schubert’s, Olive Garden, dressings, Chick-fil-A sauces and dressings, Buffalo Wild Wings sauces, Arby’s sauces, Subway sauces, Texas Roadhouse steak sauces, and frozen rolls. Its foodservice business supplies many restaurant chains in the United States with dressings, sauces, breads and frozen pastas. It operates in the Consumer Non-Cyclicals sector.
Marzetti Co is not a strong buy right now due to mixed earnings results and declining sales, despite a recent net income growth to $48.29 million, or $1.76 per share. The current price of $114.84 is significantly below the analyst price target of $130, indicating potential upside, but the company faces risks with a 2.2% decline in sales and a forward P/E of 36.10, suggesting overvaluation. The main risk is the declining sales trend, which could impact future earnings.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.